AROC Stock Overview
A vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
AroCell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.38 |
| 52 Week High | SEK 0.66 |
| 52 Week Low | SEK 0.30 |
| Beta | 1.33 |
| 1 Month Change | -5.42% |
| 3 Month Change | -26.86% |
| 1 Year Change | -12.73% |
| 3 Year Change | -52.53% |
| 5 Year Change | -68.40% |
| Change since IPO | -88.36% |
Recent News & Updates
Recent updates
Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?
Apr 20
Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)
Feb 27At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?
Nov 07We Think AroCell (STO:AROC) Can Afford To Drive Business Growth
Aug 10AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans
Apr 18We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely
Jan 03
Shareholder Returns
| AROC | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -3.5% | -1.6% | -2.7% |
| 1Y | -12.7% | 16.5% | 4.6% |
Return vs Industry: AROC underperformed the Swedish Life Sciences industry which returned 16.5% over the past year.
Return vs Market: AROC underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| AROC volatility | |
|---|---|
| AROC Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: AROC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: AROC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 22 | Anders Hultman | www.arocell.com |
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever.
AroCell AB (publ) Fundamentals Summary
| AROC fundamental statistics | |
|---|---|
| Market cap | SEK 88.46m |
| Earnings (TTM) | -SEK 50.57m |
| Revenue (TTM) | SEK 51.58m |
1.7x
P/S Ratio-1.7x
P/E RatioIs AROC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AROC income statement (TTM) | |
|---|---|
| Revenue | SEK 51.58m |
| Cost of Revenue | SEK 45.11m |
| Gross Profit | SEK 6.47m |
| Other Expenses | SEK 57.05m |
| Earnings | -SEK 50.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 12.55% |
| Net Profit Margin | -98.04% |
| Debt/Equity Ratio | 0% |
How did AROC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AroCell AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Bergman | Redeye |